Dr Agarwals Health Care Ltd (AGARWALEYE) is currently trading at 527.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Dr. Agarwal's Healthcare Limited is a leading eye-care hospital chain in India offering comprehensive ophthalmology services—cataract, glaucoma, cornea, retina, refractive surgery and related outpatient services—operating a network of 285 facilities across 14 states and 5 union territories with an international footprint of 15 facilities in Africa. Q1 FY27 results show robust scale: revenue from operations of INR 614 crore (up 26% YoY), total income INR 620 crore, Ind AS EBITDA INR 177 crore with 28.5% EBITDA margin and PAT margin expansion to 8.9%, driven by surgical mix and operational leverage despite greenfield losses. Network expansion is the primary growth lever: the company launched 18 greenfield facilities in Q1 FY27 (16 surgical), has added 166 greenfield facilities since FY23, and plans to add 60 facilities in FY27 supported by a 30-plus signed LOI pipeline and repeatable site-selection and clinical onboarding playbook. Clinical innovation and premiumization are accelerating value per surgery: high-end cataract surgeries 29.3% of cataracts, Femto robotic cataract procedures grew 33.4% YoY, SMILE refractive and retinal procedures showing strong double-digit growth, and proprietary PPP procedure with global recognition is being scaled across the network.

Over the past 52 weeks, Dr Agarwals Health Care Ltd has traded between a low of ₹402.10 and a high of ₹567.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Dr Agarwals Health Care Ltd has a market capitalization of approximately 16,250.11. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Dr Agarwals Health Care Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 87.79 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 16,250.11 Cr, Dr Agarwals Health Care Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Dr Agarwals Health Care Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Dr Agarwals Health Care Ltd is 87.79. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

NCLT Chennai sanctioned the scheme of amalgamation in which Dr. Agarwal’s Eye Hospital Limited merges into Dr. Agarwal’s Health Care Limited.

Standalone revenue from operations rose 22.28% to ₹142.97 crore, EBITDA increased to ₹45.22 crore, and net profit grew 35.46% to ₹23.38 crore in Q1FY27.

The Uniresearch trailing-growth estimate pegs Q1 FY27 revenue at ₹565-650 crore, based on a Q1 FY26 base of ₹501 crore.

Equity shareholders and unsecured creditors will vote on a Scheme of Amalgamation to merge Dr. Agarwal’s Eye Hospital Limited into Dr. Agarwals Health Care Limited, as directed by the NCLT.